Global disease experts say little is known about China's experience with long-term COVID effects thought to have afflicted millions with debilitating fatigue, brain fog and other symptoms
Mexico approves emergency use of Pfizer's COVID-19 pills
Mexican health regulator COFEPRIS said on Friday it had approved US pharmaceutical company Pfizer's antiviral oral treatment against COVID-19 for emergency use in adults with light or moderate risk of complications.
Published : 15 Jan 2022, 04:37 AM
Updated : 15 Jan 2022, 04:37 AM
Paxlovid, which combines nirmatrelvir and ritonavir in a tablet, will require a prescription, it said in a statement.
The treatment was nearly 90% effective in preventing hospitalisations and deaths, and data suggested it retains its effectiveness against the omicron variant, Pfizer has said.
Late last year, COFEPRIS had approved a similar treatment by Eli Lilly and Co.
RELATED STORIES
The demonstrations helped to end COVID restrictions but failed to achieve lasting political change, six participants based in China and overseas say
The agency seeks details on an increase in respiratory illnesses and reported clusters of pneumonia in children, which its China office called a ‘routine’ check
The inquiry is examining the government's response to the coronavirus pandemic that shut large sections of the economy and killed more than 220,000 people in Britain
